Business Wire

XPRIZE and Avanci Launch Partnership to Provide Innovators with IP and Licensing Expertise

22.10.2025 15:00:00 CEST | Business Wire | Press Release

Share

XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s greatest challenges, and Avanci, the independent global leader in one-stop IP licensing platforms, today announced a partnership to empower XPRIZE innovators.

For more than three decades, XPRIZE competitions have ignited bold solutions that ripple far beyond the competition itself to transform industries, inspire new technologies, and build an extraordinary global ecosystem of innovators dedicated to problem solving. This partnership with Avanci ensures that XPRIZE teams and alumni have access to the expertise and resources they need to protect, scale, and amplify their impact in the real world through access to Avanci’s expertise and experience in intellectual property (IP) protection and licensing. Tailored support from Avanci will help those entrepreneurs protect their breakthrough innovations, navigate complex licensing landscapes, and position them for greater success.

“The impact of our work extends well beyond the conclusion of an XPRIZE competition - the competing teams’ impact continues to shape industries and improve lives long after a prize is awarded,” said Anousheh Ansari, CEO, XPRIZE. “Our innovators have generated more than 9,700 patents and counting for work that’s driving real change across the globe. With Avanci’s expertise, we’re helping them protect and scale those breakthroughs to deliver lasting impact in every sector.”

Kasim Alfalahi, Founder and CEO of Avanci, added: “We’re inspired by XPRIZE’s mission to solve humanity’s greatest challenges through innovation. Our team brings decades of senior IP and licensing experience at many of the world’s leading companies across industries. By engaging early in the creative process, we can empower innovators to protect and scale their solutions for maximum impact. Our organizations complement one another perfectly. Together, we can help innovators realize their vision for a better world.”

Avanci has advised several XPRIZE teams across six different XPRIZE competitions, including participants in the recently awarded XPRIZE Rainforest competition. One notable example is how the company provided support to Map of Life Solutions (MOL), who won $2 million as one of the leading teams in demonstrating the most innovative technology for exploring Earth’s biodiversity.

As Map of Life Solutions aims to commercialize its biodiversity intelligence platform and expand access to scalable biodiversity measurement tools, they came to Avanci with complex questions around intellectual property and data licensing for foundational global biodiversity datasets. Avanci supported them by providing legal and strategic guidance to clarify data-use rights and assess IP protection options.

“Avanci’s support helped us navigate one of the most critical steps in turning a global biodiversity science platform into a viable business,” said Chrissy Durkin, CCO of Map of Life Solutions. “Their expertise gave us the confidence that our data-driven innovation could scale responsibly—protecting both our technology and the integrity of the science behind it.”

Avanci also supported XPRIZE Carbon Removal competitor, BIOSORRA, a company focused on biochar carbon removal solutions, aiming to build a robust IP strategy that protects their scientific and technological innovations, while supporting company scalability, business goals, and the positive impact of their work.

"We leveraged Avanci’s expertise to strengthen BIOSORRA’s intellectual property framework, ensuring it evolves alongside our growth, safeguards our technological advancements all towards enhancing brand reputation, and reinforces our mission-driven innovation,” said Inés Serra Baucells, Co-Founder and CEO, BIOSORRA.

The next phase of the Avanci and XPRIZE partnership is to develop tools to protect and support IP that can be shared across XPRIZE’s Alumni Network of 650 teams.

The partnership announcement comes ahead of XPRIZE’s annual Visioneering event taking place in Malibu, California October 23-25, 2025, where leaders from around the world convene to explore future prize concepts. Avanci will be a sponsor of the event and will join a panel discussion to share insights and early learnings from supporting XPRIZE teams through this new collaboration.

About XPRIZE

XPRIZE is the recognized global leader in designing and executing large-scale competitions to solve humanity’s greatest challenges. For over 30 years, our unique model has democratized crowd-sourced innovation and scientifically scalable solutions that accelerate a more equitable and abundant future. Donate, learn more, and co-architect a world of abundance with us at xprize.org.

About Avanci

Avanci believes that sharing patented technology can be simpler. A global independent intermediary not owned or controlled by licensors or licensees, Avanci works at the intersection of different industries. Our one-stop solutions are designed to bring efficiency, convenience, and predictability to the licensing process. Since 2016, Avanci has been driving innovation forward by making connections through our licensing platforms. www.avanci.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251022512362/en/

Contacts

Media contact:
Caitlin Chase
Senior Director of Communications
Caitlin.chase@xprize.org
210-386-1785

Ryan Peal
Senior Vice President, Marketing & Communications
media@avanci.com
310-490-1915

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye